Venetoclax + FLUDARABINE for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 14 Nov 2025: Trial registered, NCT07228273
  2. 12 Dec 2025: Trial started, NCT07228273

The trials

NCT07228273: Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

State
Under way
Phase
Phase 2
People
102 planned
Started
12 Dec 2025
Primary completion
24 Jun 2029
Arms
Arm 1 (fludarabine, cytarabine, idarubicin, venetoclax)
Results
None posted
  1. 14 Nov 2025: Trial registered
  2. 12 Dec 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.